Table 2 Stepwise regression analysis for all dialysis patients with 5-year survival rate, n = 5249

Age > 60 year

2.74 (2.45–3.07)

2.32 (2.08–2.61)

Gender—male

1.06 (0.96–1.18)

1.00 (0.95–1.05)

Grouping

 NDD

1

1

 IDD

1.23 (1.09–1.37)

1.35 (1.20–1.52)

 PDD-M

1.46 (1.19–1.78)

1.52 (1.25–1.86)

 PDD-NM

2.58 (2.16–3.07)

2.12 (1.77–2.53)

Region

 Northern

1

 Central

1.08 (0.95–1.22)

 Southern/Eastern

0.92 (0.82–1.03)

Insured premium (NT$)

 < 15,840

1

1

 15,840–25,000

0.84 (0.74–0.94)

0.86 (0.75–0.96)

 > 25,000

0.72 (0.63–0.82)

0.85 (0.74–0.97)

Urbanization

 Urban

1

 Sub-urban

1.11 (0.99–1.24)

 Rural

1.23 (1.05–1.43)

Hospital characteristics

 Medical center

1

 Region/others

1.01 (0.91 -1.13)

Number of admissions during the 12 months leading up to dialysis

 0–1

1

1

 > 1

1.87 (1.69–2.07)

1.60 (1.42–1.80)

Dialysis modality

 Peritoneal dialysis

1

 Hemodialysis

1.76 (1.40–2.22)

Comorbidity

 Hypertension

1.22 (1.10–1.36)

0.78 (0.69–0.88)

 Hyperlipidemia

0.78 (0.69–0.88)

 Gout

0.91 (0.78–1.07)

 Congestive heart failure

1.37 (1.23–1.52)

1.15 (1.03–1.28)

 Cerebrovascular accident

1.51 (1.33–1.71)

1.26 (1.11–1.43)

 COPD

1.84 (1.58–2.14)

1.34 (1.14–1.56)

 Chronic liver disease

1.57 (1.30–1.90)

1.36 (1.12–1.66)

 Malignancy

1.81 (1.57–2.09)

1.39 (1.20–1.61)

ACEI/ARB use

0.58 (0.52–0.64)

0.68 (0.62–0.76)

Lipid-lowering drug use

0.50 (0.44–0.57)

0.61 (0.54–0.69)